Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Pharmacological modulation of SAMHD1 activity by CDK4/6 inhibitors improves anticancer therapy

  • Castellví, Marc
  • Felip, Eudald|||0000-0002-3812-1313
  • Ezeonwumelu, I.J.|||0000-0003-4007-2212
  • Badia, Roger|||0000-0003-3982-7577
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Pujantell, Maria|||0000-0002-9471-5853
  • Gutiérrez-Chamorro, Lucía|||0000-0002-7649-951X
  • Teruel, Iris|||0000-0002-5563-6562
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Margelí, Mireia|||0000-0003-3594-4530
  • Ballana, Ester|||0000-0002-5215-7363
Sterile alpha motif and histidine-aspartic acid domain-containing protein 1 (SAMHD1) is a dNTP triphosphohydrolase involved in the regulation of the intracellular dNTP pool, linked to viral restriction, cancer development and autoimmune disorders. SAMHD1 function is regulated by phosphorylation through a mechanism controlled by cyclin-dependent kinases and tightly linked to cell cycle progression. Recently, SAMHD1 has been shown to decrease the efficacy of nucleotide analogs used as chemotherapeutic drugs. Here, we demonstrate that SAMHD1 can enhance or decrease the efficacy of various classes of anticancer drug, including nucleotide analogues, but also anti-folate drugs and CDK inhibitors. Importantly, we show that selective CDK4/6 inhibitors are pharmacological activators of SAMHD1 that act by inhibiting its inactivation by phosphorylation. Combinations of a CDK4/6 inhibitor with nucleoside or folate antimetabolites potently enhanced drug efficacy, resulting in highly synergic drug combinations (CI < 0.04). Mechanistic analyses reveal that cell cycle-controlled modulation of SAMHD1 function is the central process explaining changes in anticancer drug efficacy, therefore providing functional proof of the potential of CDK4/6 inhibitors as a new class of adjuvants to boost chemotherapeutic regimens. The evaluation of SAMHD1 expression in cancer tissues allowed for the identification of cancer types that would benefit from the pharmacological modulation of SAMHD1 function. In conclusion, these results indicate that the modulation of SAMHD1 function may represent a promising strategy for the improvement of current antimetabolite-based treatments.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CD32 expression is associated to T-cell activation and is not a marker of the HIV-1 reservoir

  • Badia, Roger|||0000-0003-3982-7577
  • Ballana, Ester|||0000-0002-5215-7363
  • Castellví, Marc
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Pujantell, Maria|||0000-0002-9471-5853
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Prado, Julia G.|||0000-0002-5439-4645
  • Puig, Jordi|||0000-0002-4075-0346
  • Martinez, Miguel Angel|||0000-0002-6681-4950
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Este, José|||0000-0002-1436-5823
CD32 has been shown to be preferentially expressed in latently HIV-1-infected cells in an in vitro model of quiescent CD4 T cells. Here we show that stimulation of CD4+ T cells with IL-2, IL-7, PHA, and anti-CD3/CD28 antibodies induces T-cell proliferation, co-expression of CD32 and the activation of the markers HLA-DR and CD69. HIV-1 infection increases CD32 expression. 79.2% of the CD32+/CD4+ T cells from HIV+ individuals under antiretroviral treatment were HLA-DR+. Resting CD4+ T cells infected in vitro generally results in higher integration of provirus. We observe no difference in provirus integration or replication-competent inducible latent HIV-1 in CD32+ or CD32- CD4+ T cells from HIV+ individuals. Our results demonstrate that CD32 expression is a marker of CD4+ T cell activation in HIV+ individuals and raises questions regarding the immune resting status of CD32+ cells harboring HIV-1 proviruses. CD32 has been previously shown to be expressed preferentially by CD4 T cells latently harbouring HIV-1. Here the authors show that CD32 expression in CD4 T cells is associated with T cell activation, is up-regulated by HIV-1 infection and importantly does not appear to represent an enriched cellular niche for latent HIV-1.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

RNA editing by ADAR1 regulates innate and antiviral immune functions in primary macrophages

  • Pujantell, Maria|||0000-0002-9471-5853
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Badia, Roger|||0000-0003-3982-7577
  • Castellví, Marc
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Sirera, Guillem|||0000-0003-4014-9355
  • Puig Oliva, Teresa
  • Ramirez Soto, Cristina
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Este, José|||0000-0002-1436-5823
  • Ballana, Ester|||0000-0002-5215-7363
ADAR1-dependent A-to-I editing has recently been recognized as a key process for marking dsRNA as self, therefore, preventing innate immune activation and affecting the development and resolution of immune-mediated diseases and infections. Here, we have determined the role of ADAR1 as a regulator of innate immune activation and modifier of viral susceptibility in primary myeloid and lymphoid cells. We show that ADAR1 knockdown significantly enhanced interferon, cytokine and chemokine production in primary macrophages that function as antiviral paracrine factors, rendering them resistant to HIV-1 infection. ADAR1 knockdown induced deregulation of the RLRs-MAVS signaling pathway, by increasing MDA5, RIG-I, IRF7 and phospho-STAT1 expression, an effect that was partially rescued by pharmacological blockade of the pathway. In summary, our results demonstrate a role of ADAR1 in regulating innate immune function in primary macrophages, suggesting that macrophages may play an essential role in disease associated to ADAR1 dysfunction. We also show that viral inhibition is exclusively dependent on innate immune activation consequence of ADAR1 knockdown, pointing towards ADAR1 as a potential target to boost antiviral immune response.